Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$45.42 USD

45.42
847,455

-0.09 (-0.20%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $45.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session

Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session

Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

NuVasive's (NUVA) MaXcess Retractor Study Results Positive

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?

Is (QGEN) Outperforming Other Medical Stocks This Year?

Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio

Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.

Verastem (VSTM) Jumps: Stock Rises 7.1%

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Walgreens' Pharmacy International Arm Faces Coronavirus Woes

Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.

Integra (IART) Preliminary Q3 Results Show Recovery in Sales

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing

The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.

Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries

Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries

Urmimala Biswas headshot

Coronavirus Drives Testing Stocks: Is There Room for More Upside?

Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.

Here's Why You Should Add Globus Medical to Your Portfolio

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Urmimala Biswas headshot

LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA

According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.

Align Technology Rides on Invisalign Amid Coronavirus Woes

Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.

Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications

Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.

Nilanjan Banerjee headshot

Buy These 5 Low-Beta Stocks to Survive the Choppy Market

To combat market volatility, create a portfolio of low-beta stocks.

Here's Why Qiagen (QGEN) is a Great Momentum Stock to Buy

Does Qiagen (QGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes

There has been a steady recovery in the Base Business of LabCorp (LH).

Insulet (PODD) Hits a New 52-Week High: What's Driving It?

Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.

Thermo Fisher Rides on End Market Growth, Test Revenues

Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.

Here's Why You Should Hold on to Hologic (HOLX) Stock for Now

Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.

Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing

The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.

Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)

Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.

Debanjana Dey headshot

3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic

Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.